Department of Obstetrics and Gynecology, McMaster University, Ontario, Canada.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada.
Am J Perinatol. 2024 Mar;41(4):395-404. doi: 10.1055/s-0042-1760386. Epub 2023 Feb 1.
Multiple courses versus a single course of antenatal corticosteroids (ACS) have been associated with mild respiratory benefits but also adverse outcomes like smaller head circumference and birth weight. Long-term effects warrant study. We systematically reviewed long-term outcomes (≥1 year) in both preterm and term birth after exposure to preterm multiple courses (including a rescue dose or course) versus a single course. We searched seven databases from January 2000 to October 2021. We included follow-up studies of randomized controlled trials (RCTs) and cohort studies with births occurring in/after the year 2000, given advances in perinatal care. Two reviewers assessed titles/abstracts, articles, quality, and outcomes including psychological disorders, neurodevelopment, and anthropometry. Six follow-up studies of three RCTs and two cohort studies (over 2,860 children total) met inclusion criteria. Among children born preterm, randomization to multiple courses versus a single course of ACS was not associated with adjusted beneficial or adverse neurodevelopmental/psychological or other outcomes, but data are scant after a rescue dose (120 and 139 children, respectively, low certainty) and nonexistent after a rescue course. For children born at term (i.e., 27% of the multiple courses of ACS 5-year follow-up study of 1,728 preterm/term born children), preterm randomization to multiple courses (at least one additional course) versus a single course was significantly associated with elevated odds of neurosensory impairment (adjusted odds ratio = 3.70, 95% confidence interval: 1.57-8.75; 212 and 247 children, respectively, moderate certainty). In this systematic review of long-term outcomes after multiple courses versus a single course of ACS, there were no significant benefits or risks regarding neurodevelopment in children born preterm but little data after one rescue dose and none after a rescue course. However, multiple courses (i.e., at least one additional course) should be considered cautiously: after term birth, there are no long-term benefits but neurosensory harms. KEY POINTS: · We systematically reviewed the long-term impact of multiple versus a single course of ACS.. · Long-term follow-up data were scant after a rescue dose and absent after one rescue course of ACS.. · In children born preterm, multiple courses of ACS were not associated with long-term benefits/harms.. · In children born at term, multiple courses of ACS were associated with neurosensory impairment.. · Preterm administration of multiple courses of ACS should be considered cautiously..
多疗程与单疗程产前皮质激素(ACS)治疗与轻度呼吸获益相关,但也与小头围和出生体重等不良结局相关。长期影响值得研究。我们系统地回顾了在早产儿和足月出生后接受 ACS 多疗程(包括挽救剂量或疗程)与单疗程治疗的长期结局(≥1 年)。我们从 2000 年 1 月至 2021 年 10 月搜索了七个数据库。我们纳入了随访研究随机对照试验(RCT)和队列研究,这些研究的分娩发生在/之后 2000 年,考虑到围产期护理的进步。两名审查员评估了标题/摘要、文章、质量和结局,包括心理障碍、神经发育和人体测量学。符合纳入标准的是三项 RCT 和两项队列研究的六项随访研究(共 2860 多名儿童)。在早产儿中,随机分配到多疗程与单疗程 ACS 治疗与调整后的神经发育/心理或其他结局无显著关联,但挽救剂量后数据较少(分别为 120 名和 139 名儿童,低确定性),挽救疗程后无数据。对于足月出生的儿童(即 ACS 5 年随访研究中早产儿/足月出生儿童的 27%),随机分配到多疗程(至少再增加一个疗程)与单疗程与神经感觉损伤的风险显著增加相关(调整后的比值比=3.70,95%置信区间:1.57-8.75;分别为 212 名和 247 名儿童,中度确定性)。在这项关于 ACS 多疗程与单疗程的长期结局的系统评价中,早产儿出生的儿童在神经发育方面没有显著的获益或风险,但挽救剂量后数据较少,挽救疗程后没有数据。然而,多疗程(即至少再增加一个疗程)应谨慎考虑:在足月出生后,没有长期获益,但有神经感觉损害。要点:·我们系统地回顾了多疗程与单疗程 ACS 治疗的长期影响。·挽救剂量后长期随访数据较少,挽救疗程后无数据。·在早产儿中,多疗程 ACS 与长期获益/危害无关。·在足月出生的儿童中,多疗程 ACS 与神经感觉损伤相关。·应谨慎考虑在早产儿中给予多疗程 ACS。